Literature DB >> 10623687

Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.

G Bacci1, S Ferrari, F Bertoni, S Rimondini, A Longhi, P Bacchini, C Forni, M Manfrini, D Donati, P Picci.   

Abstract

PURPOSE: The identification of prognostic factors in patients with nonmetastatic Ewing's sarcoma could allow the use of risk-adapted therapeutic strategies of treatment. PATIENTS AND METHODS: Data on 359 patients with nonmetastatic Ewing's sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered. The influence of clinical, hematologic, therapeutic, and histologic parameters on event-free survival was assessed.
RESULTS: By univariate analysis, the following features were found to be associated with a poor prognosis: male sex (P <.02), age older than 12 years (P <.006), fever (P <.0001), anemia (P <.0025), high serum lactate dehydrogenase (LDH) level (P <.0001), axial location (P <.04), radiation therapy only for local control (P <.009), type of chemotherapy regimen (P <.0001), and poor chemotherapy-induced necrosis (P <.001). After multivariate analysis, the adverse independent prognostic factors were male sex (P <.04), age older than 12 years (P <.001), fever (P <.0002), anemia (P <.02), high serum LDH level (P <.0003), axial location (P <.02), and type of chemotherapy regimen (P <.0003). When the multivariate analysis was restricted to surgically treated patients, the adverse independent prognostic factors were poor chemotherapy-induced necrosis (P <.0001), fever (P <.015), anemia (P <.02), and high serum LDH level (P <.025).
CONCLUSION: The prognosis in cases of nonmetastatic Ewing's sarcoma is influenced by many different clinical and hematologic variables, all of which are to be considered when patients are being stratified according to the risk of relapse. In surgically treated patients, the most important prognostic factor is chemotherapy-induced necrosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623687     DOI: 10.1200/JCO.2000.18.1.4

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  74 in total

1.  Factors affecting outcomes in patients treated surgically for upper extremity tumors and tumor-like lesions.

Authors:  Jesse E Otero; Christopher M Graves; Ashley TeKippe; Joseph A Buckwalter; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2013

2.  Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.

Authors:  Selmin Ataergin; Ahmet Ozet; Luis Solchaga; Mustafa Turan; Murat Beyzadeoglu; Kaan Oysul; Fikret Arpaci; Seref Komurcu; Serdar Surenkok; Mustafa Ozturk
Journal:  Med Oncol       Date:  2008-11-07       Impact factor: 3.064

3.  Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support.

Authors:  Antonio Llombart-Bosch; Isidro Machado; Samuel Navarro; Franco Bertoni; Patrizia Bacchini; Marco Alberghini; Apollon Karzeladze; Nikita Savelov; Semyon Petrov; Isabel Alvarado-Cabrero; Doina Mihaila; Philippe Terrier; Jose Antonio Lopez-Guerrero; Piero Picci
Journal:  Virchows Arch       Date:  2009-10-17       Impact factor: 4.064

Review 4.  Imaging pediatric bone sarcomas.

Authors:  Sue C Kaste
Journal:  Radiol Clin North Am       Date:  2011-06-16       Impact factor: 2.303

Review 5.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

6.  Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.

Authors:  Mingzhi Zhu; Fang Wang; Hailong Mi; Lin Li; Jing Wang; Mingli Han; Yuanting Gu
Journal:  Cell Cycle       Date:  2020-10-30       Impact factor: 4.534

Review 7.  Children's Oncology Group's 2013 blueprint for research: bone tumors.

Authors:  Richard Gorlick; Katherine Janeway; Stephen Lessnick; R Lor Randall; Neyssa Marina
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

8.  Clinical features and outcomes in patients with secondary Ewing sarcoma.

Authors:  Mark A Applebaum; Robert Goldsby; John Neuhaus; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

9.  Ewing sarcoma of the thoracic epidural space in a young child.

Authors:  Shinsuke Kobayashi; Jun Takahashi; Kazuo Sakashita; Mana Fukushima; Hiroyuki Kato
Journal:  Eur Spine J       Date:  2012-08-21       Impact factor: 3.134

10.  The epidemiology of bone cancer in 0 - 39 year olds in northern England, 1981 - 2002.

Authors:  Rachel Eyre; Richard G Feltbower; Peter W James; Karen Blakey; Emmanuel Mubwandarikwa; David Forman; Patricia A McKinney; Mark S Pearce; Richard J Q McNally
Journal:  BMC Cancer       Date:  2010-07-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.